A Pilot Randomized Controlled Trial of Transdiagnostic Network-Informed Personalized Treatment for Eating Disorders versus Enhanced Cognitive Behavioral Therapy
Abstract
Objective: Eating disorders (EDs) are serious mental illnesses with high mortality and relapse rates and carry significant societal and personal costs. Nevertheless, there are few evidenced-based treatments available. One aspect that makes treatment difficult is the high heterogeneity in symptom presentation. This heterogeneity makes it challenging for clinicians to identify pertinent treatment targets. Personalized treatment based on idiographic models may be well-suited to address this heterogeneity, and, in turn, presumably improve treatment outcomes. Method: In the current randomized controlled trial (RCT), participants will be randomly assigned to either 20 sessions of Enhanced Cognitive Behavioral (CBT-E) therapy or Transdiagnostic Network-Informed Personalized Treatment (T-NIPT-ED) for EDs. Assessment of ED symptoms, clinical impairment, and quality of life will occur at pre-, mid-, posttreatment, and one-month follow-up. Results: We will examine the acceptability and feasibility of T-NIPT-ED compared to CBT-E. We also will test the initial clinical efficacy of T-NIPT-ED versus CBT-E on clinical outcomes (i.e., ED symptoms, body mass index, and quality of life). Finally, we will test if the network-identified precision targets are the mechanisms of change. Discussion: Ultimately, this research may inform the development and dissemination of evidenced-based personalized treatments for EDs and serve as an exemplar for personalized treatment development across the…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.